A carregar...
P041 Alemtuzumab-related haemophagocytic lymphohistiocytosis: negotiating the cytokine storm
Background/Aims Alemtuzumab is an efficacious therapy for relapsing remitting multiple sclerosis (RRMS) preventing neural damage and reducing relapse rate by up to 74%. Administered in 2 treatment cycles 12 months apart and authorised for use in > 40 countries, it is a humanized monoclonal antib...
Na minha lista:
| Publicado no: | Rheumatology (Oxford) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8135612/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keab247.038 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|